These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

728 related articles for article (PubMed ID: 19595447)

  • 1. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).
    Tiihonen J; Lönnqvist J; Wahlbeck K; Klaukka T; Niskanen L; Tanskanen A; Haukka J
    Lancet; 2009 Aug; 374(9690):620-7. PubMed ID: 19595447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study.
    Tiihonen J; Wahlbeck K; Lönnqvist J; Klaukka T; Ioannidis JP; Volavka J; Haukka J
    BMJ; 2006 Jul; 333(7561):224. PubMed ID: 16825203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study.
    De Hert M; Correll CU; Cohen D
    Schizophr Res; 2010 Mar; 117(1):68-74. PubMed ID: 20060684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland.
    Tiihonen J; Tanskanen A; Bell JS; Dawson JL; Kataja V; Taipale H
    Lancet Psychiatry; 2022 May; 9(5):353-362. PubMed ID: 35334224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up.
    Taipale H; Mehtälä J; Tanskanen A; Tiihonen J
    Schizophr Bull; 2018 Oct; 44(6):1381-1387. PubMed ID: 29272458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
    Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
    JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
    Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
    J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.
    Lewis SW; Barnes TR; Davies L; Murray RM; Dunn G; Hayhurst KP; Markwick A; Lloyd H; Jones PB
    Schizophr Bull; 2006 Oct; 32(4):715-23. PubMed ID: 16540702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.
    Baandrup L; Gasse C; Jensen VD; Glenthoj BY; Nordentoft M; Lublin H; Fink-Jensen A; Lindhardt A; Mortensen PB
    J Clin Psychiatry; 2010 Feb; 71(2):103-8. PubMed ID: 19895781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic treatment and mortality in schizophrenia.
    Torniainen M; Mittendorfer-Rutz E; Tanskanen A; Björkenstam C; Suvisaari J; Alexanderson K; Tiihonen J
    Schizophr Bull; 2015 May; 41(3):656-63. PubMed ID: 25422511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland.
    Rubio JM; Kane JM; Tanskanen A; Tiihonen J; Taipale H
    Lancet Psychiatry; 2024 Jun; 11(6):443-450. PubMed ID: 38697177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
    Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
    Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. All-cause mortality and medication risk factors in schizophrenia: a prospective cohort study.
    Tenback D; Pijl B; Smeets H; Os Jv; Harten Pv
    J Clin Psychopharmacol; 2012 Feb; 32(1):31-5. PubMed ID: 22198442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
    Wheeler AJ
    Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up.
    Kiviniemi M; Suvisaari J; Koivumaa-Honkanen H; Häkkinen U; Isohanni M; Hakko H
    Schizophr Res; 2013 Oct; 150(1):274-80. PubMed ID: 23953217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary.
    Bitter I; Katona L; Zámbori J; Takács P; Fehér L; Diels J; Bacskai M; Lang Z; Gyáni G; Czobor P
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1383-90. PubMed ID: 23477752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia.
    Luykx JJ; Correll CU; Manu P; Tanskanen A; Hasan A; Tiihonen J; Taipale H
    JAMA Psychiatry; 2024 Oct; 81(10):967-975. PubMed ID: 38922592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The unchanging mortality gap for people with schizophrenia.
    Chwastiak LA; Tek C
    Lancet; 2009 Aug; 374(9690):590-2. PubMed ID: 19595448
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 37.